Modality
Cell Therapy
MOA
PD-1i
Target
KRASG12D
Pathway
Checkpoint
ASMigraine
Development Pipeline
Preclinical
~Jan 2017
→ ~Apr 2018
Phase 1
Jul 2018
→ Sep 2031
Phase 1Current
NCT03348017
1,287 pts·Migraine
2021-02→2025-12·Terminated
NCT03120189
1,321 pts·Migraine
2018-07→2031-09·Completed
2,608 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-12-014mo agoInterim· Migraine
2031-09-055.4y awayInterim· Migraine
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P1
Complet…
P1
Termina…
Catalysts
Interim
2025-12-01 · 4mo ago
Migraine
Interim
2031-09-05 · 5.4y away
Migraine
CompletedTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03348017 | Phase 1 | Migraine | Terminated | 1287 | EASI-75 |
| NCT03120189 | Phase 1 | Migraine | Completed | 1321 | PASI75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Rilulemzoparlimab | Novartis | Phase 2/3 | KRASG12D | |
| BMY-2495 | Bristol-Myers Squibb | Phase 3 | KRASG12D | |
| SNY-2934 | Sanofi | Phase 3 | KRASG12D | |
| Talainavolisib | Novo Nordisk | Preclinical | KRASG12D | |
| GSK-7987 | GSK | Phase 3 | MDM2 | |
| GIL-2037 | Gilead Sciences | Approved | KRASG12D | |
| Nirabrutinib | BioNTech | Phase 2/3 | CDK2 | |
| Cevinaritide | Genmab | Phase 2/3 | DLL3 | |
| NBI-408 | Neurocrine | Phase 2/3 | KRASG12D | |
| 207-2754 | Samsung Biologics | Phase 1/2 | KRASG12D |